A Trial to Evaluate the Safety and Tolerability of DV700P-RNA and DV701B1.1-RNA Immunization in Combination With Antiretroviral Analytical Treatment Interruption (ATI) in People Living With HIV for Elicitation of V3-glycan Antibodies

Inclusion Criteria: * Able and willing to provide informed consent. * Age 18 to 60 years. * Documented HIV infection. * Lowest (nadir) CD4+ count between 250 and 450 cells/mm³. * On stable combination antiretroviral therapy (ART) for at least 48 weeks prior to screening. * Plasma HIV RNA \<50 copies/mL for at least 48 weeks prior to enrollment, allowing limited transient increases. * CD4+ count \>450 cells/mm³ and CD4+ percentage ≥15%. * Willing and able to comply with study visits and procedures. * Agrees not to participate in another investigational study during participation unless approved. * In general good health, with no clinically significant findings on physical exam or laboratory testing. * Hemoglobin ≥11.0 g/dL (women) or ≥13.0 g/dL (men). * Absolute neutrophil count ≥750/mm³. * Platelet count ≥100,000/mm³. * ALT \<2.5 × upper limit of normal. * Estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73 m². * Serum creatinine ≤1.1 × upper limit of normal. * Serum calcium \>8.5 mg/dL. * Blood pressure within acceptable limits. * Agrees to use condoms during the specified period when ART is interrupted until HIV RNA is undetectable. * No evidence of active hepatitis C infection. * No evidence of active hepatitis B infection. * For individuals of pregnancy potential: negative pregnancy test prior to enrollment and agreement to use effective contraception during the required study period. * Agreement not to seek pregnancy during the required study period. Exclusion …